HIMS Earnings Smashing Expectations – Hidden Gem?Just finished diving into HIMS Q3 numbers—77% YoY revenue growth? That’s beastly for a telehealth player. What’s got my attention is their aggressive push into weight-loss meds, especially compounding semaglutide alternatives. This segment alone is printing cash. If they keep up this trajectory, we’re looking at a serious long-term play, IMO. Anyone else think the street’s undervaluing their expansion potential?